Postmenopausal Vaginal Atrophy Drug Market: How Is Ospemifene...

blog ekledi Botanik

2026-05-19 11:26:23

Postmenopausal Vaginal Atrophy Drug Market: How Is Ospemifene Creating the First Oral Non-Estrogen Category?

Ospemifene oral SERM therapy — the first FDA-approved non-estrogen oral treatment for moderate-to-severe dyspareunia due to menopausal vulvovaginal atrophy representing the most significant therapeutic class innovation in the global postmenopausal vaginal atrophy drug market — creates the highest growth non-hormonal segment, with the Postmenopausal Vaginal Atrophy Drug Market...

0 Yorumlar 0 Paylaşımlar 2 Görüntülenme 0 İncelemeler